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Varroa destructor is one of the main problems in modern beekeeping. The use of highly 
selective acaricides with low toxicity to bees are used internationally to control this mite. 
One of the key acaricides is the organophosphate (OP) pro-insecticide coumaphos, that 
becomes toxic after enzymatic activation inside Varroa. We show here that mites from the 
island Andros (AN-CR) exhibits high levels of coumaphos resistance. Resistance is not 
mediated by decreased coumaphos uptake, target-site resistance, or increased 
detoxification. Reduced pro-insecticide activation by CYP was the main resistance 
mechanism, a powerful and rarely encountered evolutionary solution to insecticide 
selection pressure. After treatment with sublethal doses of [14C] coumaphos, susceptible 
mite extracts had substantial amounts of coroxon, the activated metabolite of coumaphos, 
while resistant mites had only trace amounts. This indicates a suppression of the 
cytochrome P450 (CYP) mediated activation step in the AN-CR mites. Bioassays with 
coroxon to bypass the activation step, showed that resistance was dramatically reduced. 
There are 26 CYPs present in the V. destructor genome. Transcriptome analysis revealed 
overexpression in resistant mites of CYP4DP24 and underexpression of CYP3012A6 and 
CYP4EP4. RNA interference of CYP4EP4 in the susceptible population to mimic down-
regulation seen in the resistant mites, prevented coumaphos activation, and decreased 




Honey bees pollinate the majority of crops but their survival is under threat. The bee 
parasitic mite Varroa destructor  are a major cause of honey bee decline. The successful 
control of Varroa mites depends on a small number of in-hive acaricides. Species-specific 
activation of the chemical coumaphos is a powerful “pro-drug” approach to attain this 
selective toxicity and protect bees. We identified a coumaphos-resistant Varroa population 
that escapes toxicity by downregulating the activating enzyme, a P450 monooxygenase. 
Decreased activation and toxicity is a rare but evolutionarily powerful solution to achieve 
resistance. It demonstrates that the current pro-insecticide approach is under threat, as it 
can be circumvented, and highlights the need to restart the pipeline to develop selective 








Beekeeping plays an important role in providing nutritional, economic and ecological 
security globally, with direct contribution to the economy valued >230 billion dollars per 
year (1). Bee colony collapse disorder (CCD) is a major problem internationally, leading 
to a loss of >10 million beehives in North America alone and causing dramatic economic 
losses. Several possible causes for CCD have been proposed, such as the impact and side 
effects of pesticides used in agriculture, although currently still under considerable debate 
(2). Other suggested causes include damage by pests and diseases, malnutrition, genetic 
factors, immuno-deficiencies, loss of habitat, and changing beekeeping practices. In reality 
a combination of factors are likely to be involved. 
The major bee ectoparasitic mite Varroa destructor is the most important pest for 
apiculture (3, 4) and it has been directly implicated with major economic losses (5). In 
addition to its direct parasitism effects on bee physiology and sociability, Varroa transmits 
viruses and pathogens, likely associated with CCD (6, 7). Commercial beekeepers 
primarily use selective chemical acaricides with low bee toxicity s to control Varroa 
infestation (8, 9). Given the need for selectivity, very few acaricides can be used in-hive 
and common commercial use is restricted to the pyrethroids tau-fluvalinate and flumethrin, 
the formamidine amitraz and the organophosphorus (OP) coumaphos (10).  
Coumaphos was synthesized 70 years ago for use in livestock to control insect 
ectoparasites, such as ticks, and helminths. Coumaphos is a phosphorothioate pro-
insecticide (11) that requires in vivo bioactivation by cytochrome P450 (CYP) 
monooxygenases to its active phosphate metabolite coroxon (coumaphos-oxon), which is 
an irreversible inhibitor of acetylcholinesterase (AchE) (Figure 1). 
The extensive use of acaricides against Varroa has selected resistant populations in several 
countries (12): pyrethroid (tau-fluvalinate and flumethrin) resistance has been reported in 
Europe and many other parts of the world (13); formamidine (amitraz) resistance has been 
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detected in Mexico (14) and Argentina (15); coumaphos resistance has been recorded in 
the USA and Argentina (12, 16).  
Insecticide and acaricide resistance mechanisms are typically mediated either by changes 
in the target site making it insensitive, or by changes in penetration, activation, or 
detoxification, that alters the amount of insecticide that reaches the target-site. Mutations, 
such as the L925V, L925I and L925M in the voltage gated sodium channel (VGSC), the 
target site for pyrethroids, have been associated with pyrethroid resistance in Varroa (13), 
but the resistance mechanisms for amitraz and coumaphos are unknown. However, amitraz 
target-site resistance mutations in the octopamine receptor (17) and detoxification-based 
resistance of coumaphos due to enhanced metabolism of coroxon  (Figure 1), have been 
reported for the tick Boophilus microplus (18, 19). 
Characterisation of the resistance mechanisms inVarroa has been hampered by their 
biological cycle inside hives (20). Publication of the Varroa genome sequence has now 
made resistance characterization easier (21). The development of robust reverse genetic 
(RNAi) tools (22), also facilitates functional studies for the implication of specific genes 
in the resistant phenotypes. Using these tools and classical approaches we have now 
identified the underlying cause of coumaphos resistance in a Varroa population from a 




Coumaphos resistance in Varroa  
Among six populations tested, the AN-CR population from the Aegean island Andros, 
originated from a beekeeper who used coumaphos almost exclusively for many years 
exhibited substantially reduced mortality rates (7%) (Table S1). Dose response bioassays 
were subsequently conducted to determine the strength of the phenotype. Resistance Ratio 
(RR) scaled up to 217-fold in the AN-CR compared to the coumaphos susceptible ATH-S 
population (Table 1).  
 
Penetration, detoxification and altered target-site are not involved in resistance 
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Acaricide uptake (penetration) was not significantly different between resistant and 
susceptible mites (Table S2). Analysis of detoxification enzyme activities with different 
substrates, more specifically carboxyl/choline esterase (CCE) activity measured with the 
substrates PNPA, 1-NA and 2-NA; GST activity measured with the substrate CDNB and; 
MO activity measured with the substrate 7-EC did not show any significant differences 
between the AN-CR and the ATH-S mites (Table 2). In contrast, a significant reduction of 
GST activity measured with the substrate MCB was recorded (Table 2). The isoelectric 
focusing polyacrylamide (IEF) profile of CCEs was identical between the ATH-S and AN-
CR populations (Figure S1). No significant differences, in the total AChE activity, or in 
the inhibition of AChE by coroxon or malaoxon were observed between the ATH-S and 
AN-CR populations (Table 2). 
 
Decreased coumaphos activation causes resistance  
Analysis of whole body extracts of ATH-S and AN-CR Varroa mites after treatment with 
14C coumaphos, using normal phase TLC revealed, besides the parental substrate 
(Rf=0.83), two main known metabolites and some putative unknown secondary 
metabolites: the activated phosphate metabolite coroxon (Rf=0.75); the non-toxic 
metabolite chlorferon (Rf=0.50) and some more polar compounds at around Rf=0.25 and 
lower (Figure 2). The formation (detoxification rate) of the main coumaphos detoxification 
product (inactive metabolite) chlorferon was similar between the AN-CR and the ATH-S 
populations, as was the formation of the unknown metabolites. However, a significant 
difference in the formation of coroxon, the activated toxic organophosphate acaricide was 
observed. Coroxon was readily formed in the ATH-S population, in a time dependent 
manner (Figure 2). However, this metabolite was barely detected in the resistant AN-CR 
mites, even 18 h post-treatment with 200 mg a.i./L 14C coumaphos (Figure 2).  
To confirm that the failure to activate the pro-insecticide was the cause of resistance, we 
conducted bioassays directly with coroxon, thus by-passing the activation step inside the 
mite. The bioassays showed that the resistance phenotype was dramatically alleviated 




Cytochrome P450 monooxygenases are associated with coumaphos resistance 
To investigate the transcriptional basis of coumaphos resistance in Varroa, we performed 
RNAseq on ATH-S, AN-CR and AN-CR pretreated with coumaphos (tAN-CR). After 
filtering the Illumina RNAseq dataset (Table S3) for the presence of viral sequences (Table 
S4), a differential gene expression analysis was performed between the AN-CR and the 
ATH-S population and between the coumaphos treated (tAN-CR) population and the AN-
CR population. A total of 270 differentially expressed genes (DEGs) were identified in 
AN-CR compared to ATH-S (fold change (FC) > 2 and a Benjamini-Hochberg adjusted p-
value < 0.05) (Table S5). Among them, only twelve encoded typical detoxification 
enzymes (P450s InterPro domain IPR001128), CCEs (IPR002018) and GSTs 
(IPR036282)) or proteins involved in xenobiotic transport (ABC transporters 
(IPR003439)) (Table S6). Three genes encoded CYPs: two were under-expressed 
(CYP4EP4: with TMM (trimmed mean of M values) normalized counts per million (CPM) 
between 288-594 in ATH-S vs 94-127 for AN-CR, i.e. relatively highly expressed; 
CYP3012A6: TMM normalized CPM between 14-25 in ATH-S vs 4-10 in AN-CR, i.e. 
lowly expressed) and one was over-expressed (CYP4DP24: TMM normalized CPM 
between 7-21 in ATH-S vs 27-59 in AN-CR). The coding sequence of all three CYP was 
identical in the TSA data of AN-CR and ATH-S. 
 
Only one gene was differentially expressed in the pairwise comparison between the tAN-
CR and AN-CR populations (Table S6), hence, in line with PCA analysis (Figure S2), the 
DEG profile of the AN-CR and the tAN-CR populations were highly similar, indicating 
that very limited gene expression changes are associated with exposure (induction) of the 
AN-CR to the apparently non activated coumaphos, inside these varroa mites. 
We mined the RNAseq data of the ATH-S and AN-CR population for the presence of 
mutations in the V. destructor Ace genes. The protein encoded by the V. destructor gene 
LOC111243720 showed the best BLASTp hit with T. urticae AChE (E-value 0, 54% 
identity). This gene is the ortholog of the tick Rhipicephalus (Boophilus) microplus AChE 
1 (23). The protein encoded by LOC111246636 was the second best BLASTp hit to T. 
urticae AChE (E-value of E-101, 34% identity). This gene is the ortholog of R. microplus 
AChE 3 (23). 82.2 and 99.8 % of the CDS of LOC111243720 and 100% of the CDS of 
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LOC111246636 were covered by the RNA-seq consensus sequence of the ATH-S and AN-
CR population, respectively. No single nucleotide polymorphisms were identified 
compared to the reference genomic sequence. Thus, in agreement with our biochemical 
data, we have no evidence of AChE target site resistance in Varroa. 
 
CYPome of Varroa destructor 
The curated CYPome of V. destructor consists of 26 full length sequences. This is one of 
the the smallest CYPomes of arthropods. It is much smaller than the 63 CYPs of the 
western orchard mite, Metaseiulus occidentalis and only half the size of the CYPome of 
the honey bee, the Varroa host. The 26 Varroa CYPs form four CYP clans (Figure 3, 
Suppl. File 1), as in the spider mite and most insects. CYP307G4 of the CYP2 clan, and 
CYP302A1, 314A1 and 315A1 in the mitochondrial CYP clan are involved in ecdysteroid 
biosynthesis and are highly conserved. There was no CYP18 or CYP306 ortholog in 
Varroa, a situation similar to the spider mite Tetranychus urticae.  
 
Silencing of the CYP4EP4 prevents coumaphos activation and induces tolerance in 
susceptible Varroa 
Having established that the down regulation of two CYPs (CYP3012A6 and CYP4EP4) in 
AN-CR Varroa mites is associated with resistance, we silenced these CYPs, using RNA 
interference (RNAi), in the ATH-S susceptible population, aiming to mimic the down 
regulation in resistant mites. Silencing of CYP4EP4 significantly reduced mortality at the 
diagnostic dose by 35%, i.e. from 90.48% (95%CI = 84.92% – 96.04%) in the GFP injected 
control mites to 58.33% (95%CI = 48.16% – 68.50%) in the dsCYP4EP4 treated mites 
(Figure 4A). In contrast, silencing of the CYP3012A6 in ATH-S mites did not significantly 
reduce mortality at the diagnostic dose compared to the GFP control mites (Figure 4A). 
Silencing of CYP4EP4 but not of GFP or CYP3012A6 in the susceptible ATH-S mites was 
also associated with a substantial reduction of the activation of coumaphos to its active 
metabolite coroxon (Figure 4B). The silencing efficiency was verified by the statistically 
significant reductions in CYP4EP4 (28.7% SE = 10.3%, P = 0.032) and CYP3012A6 
(34.59% SE = 11.6%, P = 0.031) mRNA levels, respectively, compared to the GFP control 




An unusual case of CYP-mediated reduced pro-insecticide activation conferring very high 
levels of acaricide resistance in the major bee ectoparasitic mite V. destructor was 
identified and elucidated at the molecular level. OP compounds, which dominated the 
insecticide market in the 19770s-80s, are phosphorothioates (with a P=S moiety). These 
are pro-insecticides, with a 4-5 order of magnitude lower acetylcholinesterase 
inhibitionthan that of their activated metabolite, the corresponding phosphates (P=O). The 
activation step can lead to selective toxicity. For instance, malathion is rapidly inactivated 
by mammalian carboxylesterases, while insects preferentially activate it to malaoxon. The 
P=S to P=O activation step is catalyzed by CYPs, for instance house fly CYP6A1 and 
CYP12A1 (26, 27).  
Here we show that in Varroa reduced CYP-mediated activation is involved in coumaphos 
resistance. Bioassays with coroxon, which bypassed the CYP activation step, reduced the 
AN-CR resistance from 217-fold for coumaphos, to 25-fold for coroxon. The CYPome in 
Varroa is limited (N= 26) which is usual in parasitic organisms. The human body louse has 
37 CYP genes (28) and the crustacean salmon louse Lepeophtheirus salmonis just 21 (29).  
There was differential expression of three CYPs, one (CYP4DP24 from the CYP4 clan) 
over- and two underexpressed (CYP3012A6 and CYP4EP4 from the mitochondrial and 
CYP4 clan, respectively) in the AN-CR compared to ATH-S mites. Gene expression 
changes after induction by sublethal doses of coumaphos in the resistant AN-CR 
population were negligible (only one gene).  
Changes in CYP levels in both directions could in theory lead to resistance. This is because 
the CYP enzymes that attack the phosphorothioate (P=S) moiety of OP compounds (30) 
first generate a monooxygenated, unstable intermediate which can then result in two 
outcomes (see Figure 1 for coumaphos, showing the main radiolabeled metabolites). One 
outcome is ester cleavage and formation of the non-toxic metabolite chlorferon and the 
other outcome is desulfuration and formation of the activated, toxic acaricide coroxon. The 
ratio of the two products depends on the substrate and the CYP. For coumaphos, a CYP 
catalyzing a high coroxon/chlorferon ratio would favor activation over detoxification. Its 
underexpression may lead to resistance, and vice-versa (see schema – Figure S3).  
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Analysis of coumaphos metabolism indicated that there was no difference between the 
ATH-S and the AN-CR strains in the formation of chlorferon, or in the depletion of the 
parental coumaphos. However, coroxon formation was decreased in resistant mites. Thus, 
the underexpression of a CYP in the resistant population with a high ratio of coroxon 
formation is the most likely resistance mechanism.  
Despite many attempts, we were not able to functionally express the differentially regulated  
CYP enzymes to directly verify our interpretation of the in vivo metabolism studies.  
Hence, weconfirmed the resistajce mechanism using reverse genetics of the two down 
regulated CYPs. RNA interference of the down regulated CYP4EP4 in the susceptible 
strain decreased coumaphos activation and increased the tolerance to coumaphos. Thus, 
this reverse genetics manipulation mimics long term selection for selection for a down 
regulation mechanism of CYP4EP4, with similar outcome. Expression of CYP4EP4 is ~20 
times higher than CYP3012A6.  Silencing CYP3012A6 did not change the resistance 
phenotype, either because this CYP does not metabolize coumaphos or because its 
expression level is too low to affect the toxic outcome 
Most studies on OP resistance have documented the overexpression of CYP genes which 
generate a high ester cleavage (detoxification)/ desulfuration (activation) ratio, such as 
CYP6A1 in diazinon-resistant house flies (ratio 2.66, (26)). Examples of the reverse, i.e. 
decreased levels of enzymes with higher desulfuration / ester cleavage ratios have not been 
reported. However, methyl parathion resistance in a field strain of Heliothis virescens was 
associated with lower microsomal activation to methyl paraoxon, and this activation 
product had a significantly lower resistance factor (31). This situation is similar to the 
mechanism described here for coumaphos resistance in Varroa.  
The possibility that additional mechanisms may also play a role in the coumaphos 
resistance can not be excluded. For example, the reduced GST activity with the substrate 
MCB and the two downregulated GSTs (LOC111244895 and LOC111253932, Table 3) in 
the AN-CR may have a direct or supportive role in the resistance phenotype. 
Varroa infestations are associated with severe economic losses in apiculture and 
coumaphos is one of the few acaricides available for its control worldwide. The presence 
and frequency of this coumaphos resistance mechanism can now be tracked. If it is 
common, the Janus face of CYP metabolism, with different activation vs detoxification 
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profiles for different insecticides catalyzed by the same CYP, could potentially open up 
new options for Insecticide Resistance Management (IRM). For example, Adolfi et al. 
(2019) (32) showed that the overexpression of the Anopheles AgCYP6M2 CYP confers 
permethrin resistance via detoxification, and increases the susceptibility to malathion, via 
bioactivating it to its more toxic metabolite malaoxon. Similarly pyrethroid-resistant H. 
virescens  was more susceptible to the pro-insecticide chlorfenapyr (33). This negative 
cross-resistance between different insecticide/pro-insecticide classes, due to differential 
regulation of CYPs in resistant insects could be exploited in a push-pull strategy of IRM. 
 
 
Materials and Methods 
 
Chemicals and 14C-labeled coumaphos 
The following technical grade chemicals were used in the bioassays: coumaphos 98% 
purity (Sigma Aldrich, Greece), malaoxon, coumaphos-oxon 96% (LGC Standards, UK), 
3-Chloro-7-hydroxy-4-methylcoumarin (chlorferon) 97% purity (Sigma Aldrich, Greece). 
All the other reagents were obtained by Sigma Aldrich, unless otherwise stated. 
Radiolabeled [coumarin-4-14C] coumaphos (Figure 1) of high chemical and radiochemical 
purity (>99%) was purchased from Institute of Isotopes Co., Ltd. (Izotop, Hungary). The 
specific activity of the [14C] coumaphos was 2.024 MBq/mg (1MBq= 60x106dpm).  
 
Mite populations  
On the island of Andros, a population was collected from a site where coumaphos had been 
used almost exclusively for the last 14 years and where control failure was reported 
(hereafter named AN-CR, Andros Coumaphos Resistant). A Varroa population collected 
from beehives at the Agricultural University of Athens was used as a susceptible strain, as 
the bee colony has been maintained without chemical treatments for the last twenty years 
(hereafter named ATH-S, Athens Susceptible).  
 
Bioassays 
Chemicals dissolved in acetone were freshly prepared 0.5 mL of solutions was placed into 
individual 12-mL glass vials. Vials were rolled until the acetone evaporated. Batches of ten 
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(10) adult female mites were introduced into the coated vials, closed with holed parafilm, 
each time at 25 °C for 20 h. Dose response bioassays were conducted. For gene expression 
analysis described below, induction bioassays were conducted at the coumaphos LC5 for 
the AN-CR and the treated mites were collected at the end of the bioassay (tAN-CR). After 
the treatment period, mites were considered dead in absence of leg movement when 
prodded with a fine paintbrush. Toxicity data were analyzed using PoloPC (LeoRA, 
Software, Berkeley, CA, USA). Resistance ratios were calculated by dividing the LC50 of 
a population with the LC50 of the ATH-S susceptible/reference population.  
 
Detoxification enzyme activities and acetylcholinesterase inhibition  
The enzymatic activity of carboxyl/choline esterases (CCEs), monooxygenases (MOs), 
Glutathione S-transferases (GSTs) and acetylcholinesterase (AChE) was determined 
according to Van Leeuwen et al (2005) (34) with slight modifications. Briefly, mass 
homogenates were prepared by crushing 1-10 freshly sampled adult mites in sodium 
phosphate buffer (0.1M, pH 7.2, 200μl) with a Teflon pestle. The homogenate was 
centrifuged at 5000g and 4⁰C for 5 min and the resulting supernatant was used as an 
enzyme source. Approximately 10-20 μg crude protein extract was included in each assay, 
with at least 3-5 replicates for each population and assay. Fluorescence and absorbance 
were measured with a TECAN SpectraFluor microplate reader. 
For the CCE assays, the substrates p-nitrophenol (PNPA) (kinetically for 10-min), 1-
naphthyl acetate (1-NA) and 1-naphthyl acetate (2-NA) (end point after 30 minutes of 
incubation) were used. For the GST assays, the substrates 1-chloro-2,4-dinitrobenzene 
(CDNB) (kinetically, for 10-min) and monochlorobimane (MCB) (end point after 20 min) 
were used. For MO assays, the substrate 7-ethoxycoumarin was used to measure the O-
deethylation activity kinetically. 
For AChE activity and inhibition rates with the OP oxon analogues malaoxon and coroxon, 
the reaction was conducted in 0.2mL substrate-reagent solution containing 5,5’-dithio-
bis(2-nitrobenzoic acid) (DTNB) 0.5mM and acetylthiocholine (AcSCh) 1.25mM. 
Residual AChE activities, after 10-min incubation with malaoxon and coroxon (at 
concentrations 10-8M – 10-4M) were measured kinetically at 405nm. The IC50 was 
determined using GraFit Version 3.0, Erithacus Software Ltd., Staines, U.K (35).   
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Analysis of coumaphos metabolism 
Mites exposed to [14C] coumaphos vials, as described above, were washed and 
homogenized in 200µl methanol. Supernatant was collected after centrifugation (5 min at 
5,000 rpm) and the pellet was resuspended in methanol. The supernatant was reduced with 
air flow to 10 μl. Thin Layer Chromatography (TLC) was prepared by saturating the 
chamber with chloroform/methanol (100:7) and allowing to equilibrate for 1 h. 10 μl of 
each sample was spotted onto a silica gel pre-coated plate. After chromatography in 
chloroform/methanol (100:7), the position of cold coumaphos, coroxon and chlorferon was 
marked and the plate wrapped in plastic foil. Radioactivity was recorded with a 
phosphorimager (GE Healthcare Typhoon™ FLA 7000), followed by calculation of the 
retention factor (Rf) as the ratio of migration distance of the compound of interest to that 
of the solvent front. CorelDRAW Home & Studend x7 software was used for image 
processing. Cold chemistry unlabeled UV-active controls was used to localize the 14C 
determined spots, and link retention time. 
 
Illumina RNAseq 
Varroa mites were introduced in 12 mL glass vials coated with either acetone (ATH-S and 
AN-CR) or 200 mg a.i. coumaphos/L acetone (tAN-CR) and kept at 25°C for 20 h. Glass 
vials were coated as described in the Bioassays section. After 20 h, alive mites were 
collected in an Eppendorf tube (10-20 mites/tube), snap frozen with liquid nitrogen and 
stored at -80°C until RNA extraction. RNA was extracted, using the TRI reagent protocol 
(Invitrogen, Carlsbad, CA) following the manufacturer’s instructions and treated with 
TURBO™ DNase I (ThermoFisher Scientific) to remove genomic DNA contamination. 
Illumina libraries were constructed from the RNA samples with the TruSeq Stranded 
mRNA Library Preparation Kit with polyA selection (Illumina, USA), and sequenced on 
an Illumina HiSeq 2500 to generate strand-specific paired reads of 2 x 125 bp (library 
construction and sequencing was performed at the High-Throughput Genomics Core of the 
Huntsman Cancer Institute, University of Utah, Utah, USA). All RNAseq data that was 
generated during the current study is available at the Gene-Expression Omnibus (GEO) 
repository with accession number GSE153472. The quality of the reads was verified using 
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FASTQC version 0.11.5 (36) and subsequently, viral contamination was removed (Table 
S3). A PCA was created as described by Love et al 2015 (37) (Figure S1). A differential 
expression (DE) analysis was performed using voom (version 3.34.9) (38) and the read 
count data obtained by HTSeq 0.6.0. Differentially expressed genes (DEGs, log2FC >1 
and Benjamini-Hochberg adjusted p-value < 0.05) were determined for the following 
comparisons: AN-CR vs ATH-S, tAN-CR vs ATH-S and tAN-CR vs AN-CR). 
The RNAseq data of both ATH-S and AN-CR was also used to search for mutations in 
Ace, the gene(s) encoding the target-site of coumaphos. First, Varroa Ace sequences were 
identified by a BLASTp search against the Varroa proteome (version of October 2017) and 
using Tetranychus urticae Ace as query (tetur19g00850, 
http://bioinformatics.psb.ugent.be/webtools/bogas/overview/Tetur). Next, a BAM-file for 
the 4 samples of the ATH-S population and for the 8 samples of the AN-CR population 
(both AN-CR and TAN-CR) was generated by merging the individual BAM-files of the 
ATH-S and (t)AN-CR samples that were created during the STAR alignment (see 
paragraph above), respectively. Subsequently, this merged BAM-file was used to generate 
an ATH-S and AN-CR Ace consensus sequences using the “mpileup” and “call” command 
of the samtools 1.4.1 and bcftools 1.3.1 software (39), respectively and the Varroa genome 
as reference (GCF_002443255.1). The resulting FASTQ file was then converted to a 
FASTA file using the seqtk 1.2 software (using default Illumina settings: “-aQ 64 -q 20” 
as suggested on https://github.com/lh3/seqtk). Last, we assembled a de novo transcriptome 
using CLC Genomics workbench 11 (Qiagen, Belgium) with default settings, and using 24 
million random subsampled, bee virus filtered, reads (8 million/sample) from ATH-S2-
ATH-S4 and 24 million random, bee virus filtered, reads (3.42 million/sample) from AN-
CR1- AN-CR4 and tAN-CR1-tAN-CR3 (ATH-S1 and tAN-CR4 were not used for de novo 
assembly as these samples had less than ten million reads (Table S5)).  
 
Cytochrome P450 (CYP) gene annotation 
The predicted V. destructor CYP sequences from the NCBI annotation release 100 were 
manually curated for accuracy and completeness. Seven were corrected, including an 
artefactual fusion of three CYPs. In addition, one full length CYP was found in our 
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transcriptome assembly, and while not predicted in the NCBI RefSeq models, it was 
present in the genome as an intronless gene. This resulted in a CYPome of 26 full-length 
genes, for which official CYP names were obtained from Dr. D.R. Nelson (University of 
Tennessee). All CYP genes were found in the de novo transcriptome assembly (Dataset 
S1). Six partial CYP sequences and CYP pseudogenes were also found and were excluded 
from further analysis. Full-length CYP sequences were aligned by MUSCLE (40), a 
phylogeny obtained by PhyML at www.phylogeny.fr  and the tree was drawn and annotated 
with FigTree v1.4.4. (http://tree.bio.ed.ac.uk/).  
 
RNA interference functional validation assays  
Reverse genetic experiments using submersion in dsRNA were performed according to 
Campbell et al., 2010 (22). Briefly, PCR was performed on cDNA from AN-CR mites 
using Phusion High-Fidelity DNA Polymerase (Thermo Scientific) following the 
manufacturer’s instruction., with specific primer pairs designed using NCBI Primer 
BLAST to produce a product with a length of 400–600 bp and a GC content of 20–50% 
that also introduce a T7 promoter sequence: dsGFP (control), dsCYP4EP4 and 
dsCYP3012A6 (Table S2). dsRNA was created by using the Megascript Kit from Ambion 
and the T7 RNA polymerase with a 16-h 37 °C incubation, following the manufacturer’s 
instructions. The dsRNA was cleaned using a MegaClear Transcription Clear Up kit 
(Ambion). The resultant dsRNA product was analysed using a Nanodrop spectrometer 
(Nanodrop Technologies). Batches of 10 female Varroa mites were immersed into dsRNA 
(2.5 μg/ μl) for 6-12 h. Eight biological experiments were performed with each dsRNA. As 
a control, non-endogenous GFP dsRNA was used at the same concentration. 
Quantitative Real time PCR 
The efficiency of the dsRNA assays were validated by quantitative PCR (qPCR). RNA was 
extracted in a similar way as for Illumina RNAseq experiments and subsequently used for 
cDNA synthesis, using Superscript III reverse transcriptase and Oligo-dT 20 primers 
(Invitrogen, Athens, Greece). Amplification reactions of 10 μl final volume were 
performed on a CFX Connect Real-Time PCR Detection System (Bio-Rad, Hercules, CA, 
USA) and Kapa SYBR FAST qPCR Master Mix (Kapa-Biosystems), using the primers 
listed in Table S6. The thermal protocol consisted of a polymerase activation step at 95oC 
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for 3 min and 40 cycles of denaturation and annealing/extension steps at 95oC for 10 s and 
60oC for 45 s, followed by a melting curve analysis step. Two housekeeping genes, NADH 
(LOC111249888) and 18S rRNA (LOC111253957), were used as reference genes for 
normalization (41). A tenfold dilution series of pooled cDNA was used to assess the 
efficiency of the qPCR reaction for each gene specific primer pair. A no template control 
(NTC) was included to detect possible contamination and a melting curve analysis was 
done in order to check the presence of a unique PCR product. Experiments were performed 
with four biological replicates and two technical replicates for each reaction. Relative 
expression analysis was done according to Pfaffl et al., 2002 (42) and significance of 




We thank Robert Greenhalgh and Prof. Richard M. Clark (University of Utah) for help 
with sequencing, and David R. Nelson (University of Tennessee) for naming the CYP 
genes. We thank beekeepers John Rerras from Andros, Dimitris Lazarakis from Sparti and 
Ariadni Kritikou from Naxos for providing Varroa samples from their beehives for the 
bioassays, and dr. Aris Ilias (IMBB-FORTH) for helping with the analysis of bioassay data.  
 
FUNDERS 
This research has been financed by Greek national funds through the Public Investments 
Program (PIP) of General Secretariat for Research & Technology (GSRT), under the 
Emblematic Αction "The Bee Road" (project code: 2018ΣΕ01300000). SV was supported 
by Greece and the European Union (European Social Fund- ESF) through the Operational 
Programme «Human Resources Development, Education and Lifelong Learning» in the 
context of the project “Strengthening Human Resources Research Potential via Doctorate 
Research” (MIS-5000432), implemented by the State Scholarships Foundation (ΙΚΥ). 
During this study, WD was a post-doctoral research fellow of the Research Foundation 
17 
Flanders (grant 1274917N). This work was in part supported by the Research Foundation 
Flanders (FWO) (grant G053815N) and the Research Council (ERC) under the European 
Union's Horizon 2020 research and innovation program, grant 772026-POLYADAPT 
 
REFERENCES 
1.  B. L. Johnson, M. Y. Lichtveld, Environmental Policy and Public Health, Second 
Edition (CRC Press, 2017). 
2.  D. Cressey, The bitter battle over the world’s most popular insecticides. Nature 
551, 156–158 (2017). 
3.  P. Rosenkranz, P. Aumeier, B. Ziegelmann, Biology and control of Varroa 
destructor. Journal of Invertebrate Pathology 103, S96–S119 (2010). 
4.  K. S. Traynor, et al., Varroa destructor: A Complex Parasite, Crippling Honey 
Bees Worldwide. Trends in Parasitology 36, 592–606 (2020). 
5.  D. Cressey, EU states lose up to one-third of honeybees per year. Nature 15016 
(2014) (July 4, 2020). 
6.  R. M. Francis, S. L. Nielsen, P. Kryger, Varroa-virus interaction in collapsing 
honey bee colonies. PLoS ONE 8, e57540 (2013). 
7.  Y. P. Chen, R. Siede, “Honey bee viruses” in Advances in Virus Research (Elsevier, 
2007), pp. 33–80. 
8.  N. P. Aliano, M. D. Ellis, B. D. Siegfried, Acute contact toxicity of oxalic acid to 
Varroa destructor (Acari: Varroidae) and their Apis mellifera (Hymenoptera: Apidae) 
hosts in laboratory bioassays. Journal of Economic Entomology 99, 1579–1582 (2006). 
9.  N. Damiani, L. B. Gende, P. Bailac, J. A. Marcangeli, M. J. Eguaras, Acaricidal 
and insecticidal activity of essential oils on Varroa destructor (Acari: Varroidae) and Apis 
mellifera (Hymenoptera: Apidae). Parasitology Research 106, 145–152 (2009). 
10.  D. vanEngelsdorp, et al., Colony Collapse Disorder: A descriptive study. PLoS 
ONE 4, e6481 (2009). 
11.  P. Jeschke, Propesticides and their use as agrochemicals. Pest. Manag. Sci. 72, 210–
225 (2016). 
12.  M. D. Maggi, S. R. Ruffinengo, L. B. Gende, M. J. Eguaras, N. H. Sardella, LC 50 
baseline levels of amitraz, coumaphos, fluvalinate and flumethrin in populations of Varroa 
destructor from Buenos Aires Province, Argentina. Journal of Apicultural Research 47, 
292–295 (2008). 
18 
13.  J. González-Cabrera, et al., Novel mutations in the voltage-gated sodium channel 
of pyrethroid-resistant Varroa destructor populations from the Southeastern USA. PLoS 
ONE 11, e0155332 (2016). 
14.  M. M. Rodríguez, J. A. Bisset, Y. De Armas, F. Ramos, Pyrethroid insecticide-
resistant strain of Aedes aegypti from Cuba induced by deltamethrin selection. Journal of 
the American Mosquito Control Association 21, 437–445 (2005). 
15.  M. D. Maggi, S. R. Ruffinengo, P. Negri, M. J. Eguaras, Resistance phenomena to 
amitraz from populations of the ectoparasitic mite Varroa destructor of Argentina. 
Parasitol Res 107, 1189–1192 (2010). 
16.  J. S. Pettis, A scientific note on Varroa destructor resistance to coumaphos in the 
United States. Apidologie 35, 91–92 (2004). 
17.  S. W. Corley, et al., Mutation in the RmβAOR gene is associated with amitraz 
resistance in the cattle tick Rhipicephalus microplus. Proceedings of the National Academy 
of Sciences 110, 16772–16777 (2013). 
18.  D. L. Bull, E. H. Ahrens, Metabolism of coumaphos in susceptible and resistant 
strains of Boophilus microplus (Acari: Ixodidae). Journal of Medical Entomology 25, 94–
98 (1988). 
19.  A. Y. Li, R. B. Davey, R. J. Miller, J. E. George, Resistance to coumaphos and 
diazinon in Boophilus microplus (Acari: Ixodidae) and evidence for the involvement of an 
oxidative detoxification mechanism. Journal of Medical Entomology 40, 482–490 (2003). 
20.  T. Van Leeuwen, J. Vontas, A. Tsagkarakou, W. Dermauw, L. Tirry, Acaricide 
resistance mechanisms in the two-spotted spider mite Tetranychus urticae and other 
important Acari: A review. Insect Biochemistry and Molecular Biology 40, 563–572 
(2010). 
21.  M. A. Techer, et al., Divergent evolutionary trajectories following speciation in two 
ectoparasitic honey bee mites. Communications Biology 2, 357 (2019). 
22.  E. M. Campbell, G. E. Budge, A. S. Bowman, Gene-knockdown in the honey bee 
mite Varroa destructor by a non-invasive approach: studies on a glutathione S-transferase. 
Parasites Vectors 3, 73 (2010). 
23.  K. B. Temeyer, K. G. Schlechte, W. P. McDonough, Baculoviral expression of 
presumptive OP-resistance mutations in BmAChE1 of Rhipicephalus (Boophilus) 
microplus (Ixodida: Ixodidae) and biochemical resistance to OP inhibition. Journal of 
Medical Entomology 56, 1318–1323 (2019). 
24.  M. Grbić, et al., The genome of Tetranychus urticae reveals herbivorous pest 
adaptations. Nature 479, 487–492 (2011). 
25.  M. F. Feldlaufer, K. Hartfelder, Relationship of the neutral sterols and ecdysteroids 
of the parasitic mite, Varroa jacobsoni to those of the honey bee, Apis mellifera. Journal 
of Insect Physiology 43, 541–545 (1997). 
19 
26.  C. Sabourault, et al., Overproduction of a P450 that metabolizes diazinon is linked 
to a loss-of-function in the chromosome 2 ali-esterase (MdαE7) gene in resistant house 
flies: Ali-esterase and P450-mediated insecticide resistance. Insect Molecular Biology 10, 
609–618 (2001). 
27.  V. M. Guzov, G. C. Unnithan, A. A. Chernogolov, R. Feyereisen, CYP12A1, a 
mitochondrial cytochrome P450 from the house fly. Archives of Biochemistry and 
Biophysics 359, 231–240 (1998). 
28.  S. H. Lee, et al., Decreased detoxification genes and genome size make the human 
body louse an efficient model to study xenobiotic metabolism. Insect Molecular Biology 
19, 599–615 (2010). 
29.  J. L. Humble, et al., Genome-wide survey of cytochrome P450 genes in the salmon 
louse Lepeophtheirus salmonis (Krøyer, 1837). Parasites Vectors 12, 563 (2019). 
30.  D. S. Grosch, M. E. Plumb, A sex difference in radioactivity of Artemia cultured in 
sea water containing phosphorus-32. Nature 183, 122–123 (1959). 
31.  T. Konno, E. Hodgson, W. C. Dauterman, Studies on methyl parathion resistance 
in Heliothis virescens. Pesticide Biochemistry and Physiology 33, 189–199 (1989). 
32.  A. Adolfi, et al., Functional genetic validation of key genes conferring insecticide 
resistance in the major African malaria vector, Anopheles gambiae. Proceedings of the 
National Academy of Sciences 116, 25764–25772 (2019).  
33.  S. S. Pimprale, C. L. Besco, P. K. Bryson, T. M. Brown, Increased susceptibility of 
pyrethroid-resistant tobacco budworm (Lepidoptera: Noctuidae) to chlorfenapyr. Journal 
of Economic Entomology 90, 49–54 (1997). 
34.  T. Van Leeuwen, S. Van Pottelberge, L. Tirry, Comparative acaricide susceptibility 
and detoxifying enzyme activities in field-collected resistant and susceptible strains of 
Tetranychus urticae. Pest. Manag. Sci. 61, 499–507 (2005). 
35.  Leatherbarrow, R.J, GraFit Version 3.0, Erithacus Software Ltd., Staines, U.K 
(1992). 
36.  Andrews, S, FastQC: a quality control tool for high throughput sequence data 
(2010). 
37.  M. I. Love, S. Anders, V. Kim, W. Huber, RNA-Seq workflow: gene-level 
exploratory analysis and differential expression. F1000Res 4, 1070 (2015). 
38.  C. W. Law, Y. Chen, W. Shi, G. K. Smyth, Voom: precision weights unlock linear 
model analysis tools for RNA-seq read counts. Genome Biol 15, R29 (2014). 
39.  H. Li, et al., The Sequence Alignment/Map format and SAMtools. Bioinformatics 
25, 2078–2079 (2009). 
20 
40.  R. C. Edgar, MUSCLE: multiple sequence alignment with high accuracy and high 
throughput. Nucleic Acids Research 32, 1792–1797 (2004). 
41.  E. M. Campbell, C. H. McIntosh, A. S. Bowman, A toolbox for quantitative gene 
expression in Varroa destructor: RNA degradation in field samples and systematic analysis 
of reference gene stability. PLoS ONE 11, e0155640 (2016). 
42.  M. W. Pfaffl, G. W. Horgan, L. Dempfle, Relative expression software tool 
(REST(C)) for group-wise comparison and statistical analysis of relative expression results 
in real-time PCR. Nucleic Acids Research 30, 36e–336 (2002). 
 
FIGURE LEGENDS 
Figure 1. Metabolism of [14C]-coumaphos in Varroa.  Radiolabeled coumaphos (* 
indicates the position of the label) is converted to two main metabolites, chlorferon and 
coroxon. Both compounds result from P450 monooxygenation of the P=S moiety of 
coumaphos that initially leads to an unstable product in the active site. Ester cleavage to 
the non-toxic chlorferon and desulfuration to the acetylcholinesterase inhibitor coroxon are 
the two outcomes of P450 metabolism. The ratio of the two outcomes is specific to each 
P450. See text for details. 
 
Figure 2. Analysis of metabolites after in vivo treatment with [14C] coumaphos. Normal 
Phase TLC in chloroform/methanol (100/7) of whole body extracts of ATH-S and AN-CR 
mites (V. destructor) treated with [14C] coumaphos. C1: parental coumaphos (Rf=0.83); 
C2: coumaphos oxon (Rf=0.75); C3: chlorferon (Rf=0.50); C4 (Rf=0.1) unknown 
metabolites. A. Reduced activation of coumaphos to coroxon associated with resistance: 
ATH-S and AN-CR mite homogenates 2 h after treatment with [14C] coumaphos. B. Time 
dependent formation of coroxon in ATH-S but not in AN-CR Varroa mites. ATH-S mites 
after 2h, 6h and 18h in vivo treatment and AN-CR after 18 h treatment with [14C] 
coumaphos (vials coated with 200 mg a.i./L). 
 
Figure 3. Maximum likelihood phylogeny of the 26 CYP sequences of Varroa destructor. 
The four CYP clans are marked with a different color: yellow: CYP2 clan; red: CYP4 clan; 
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black: CYP3 clan; blue: mitochondrial clan. The three differentially expressed CYPs are 
marked with an asterisk. 
 
Figure 4. Silencing of the CYP4EP4 prevents coumaphos activation and induces tolerance 
in susceptible Varroa destructor. Mortality rates against coumaphos of ATH-S immersed 
for 6 h in dsRNA (GFP; CYP4EP4 and CYP3012A6) and tested with diagnostic 
coumaphos concentration (200 ppm) after 72 h. B. Normal Phase TLC of whole body 
extracts of ATH-S mites immersed for 6 h in dsRNA (GFP; CYP4EP4 and CYP3012A6) 
and treated with [14C] coumaphos as in 4A. C. Validation of gene silencing efficacy by 
RNAi. Relative expression levels in dsRNA‐submersed Varroa (GFP control, 
CYP4EP4and CYP3012A6). mRNA expression was calculated using the 2^-dCt formula 
and was normalized to housekeeping genes; * indicate statistical significance at the P < 
0.05 level, calculated using independent samples t-test; Error bars represent SE of mean.  
AU: Arbitrary Units (×20 for CYP3012A6 expression to harmonise the scale).  
 
 
